Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ADCT is 7.9 and suggests 84% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell